



August 28, 2008

Media Statement – Global Isotope Supply

MDS Nordion, a member of the nuclear medicine community, is aware of the shutdown of a nuclear reactor in the Netherlands and of its impact on medical isotope supply to meet critical patient needs worldwide.

As a global leader in providing technologies for molecular imaging, MDS Nordion is fully committed and prepared to scale up our processing capacity to deliver any extra isotope supply that we receive. Suppliers are keeping us updated on supply availability and we continue to work closely with our customers.

MDS Nordion primarily receives its isotopes from Atomic Energy of Canada Limited's (AECL) NRU reactor and processes them into medical isotopes that are distributed to our customers, radiopharmaceutical manufacturers. These manufacturers then distribute the radiopharmaceuticals to hospitals and radiopharmacies worldwide. MDS Nordion does not determine the allocation of medical isotopes to specific end users.

Approximately 30 million global nuclear medicine procedures are conducted annually to diagnose and treat potentially life-threatening conditions such as heart disease and cancer. We are concerned there is currently no reliable, long-term isotope supply solution to meet this growing demand. As a result, there is risk of isotope shortages recurring.

MDS Nordion's top priority remains doing our part to meet the needs of the global nuclear medicine community and the patients they serve.

For more information on isotope supply visit www.mdsnordion.com.